MISGAV, Israel & LONDON--(BUSINESS WIRE)--Medgenics (AIM:MEDG) announces that it has received approval from Israel’s Ministry of Health (MOH) to commence its landmark Phase I/II safety and efficacy trial of its EPODURE Biopump for providing sustained treatment of anaemia in patients with chronic kidney disease. Patient recruitment has now commenced for the trial, with the first patients expected to receive their Biopumps within six weeks.
